Your browser doesn't support javascript.
loading
Treatment of Ureteral Stent-Related Symptoms.
Pecoraro, Angela; Peretti, Dario; Tian, Zhe; Aimar, Roberta; Niculescu, Gabriel; Alleva, Giorgio; Piana, Alberto; Granato, Stefano; Sica, Michele; Amparore, Daniele; Checcucci, Enrico; Manfredi, Matteo; Karakiewicz, Pierre; Fiori, Cristian; Porpiglia, Francesco.
Afiliação
  • Pecoraro A; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Peretti D; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Tian Z; Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Québec, Canada.
  • Aimar R; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Niculescu G; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Alleva G; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Piana A; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Granato S; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Sica M; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Amparore D; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Checcucci E; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Manfredi M; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Karakiewicz P; Cancer Prognostics and Health Outcomes Unit, University of Montreal Hospital Center, Montreal, Québec, Canada.
  • Fiori C; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
  • Porpiglia F; Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy.
Urol Int ; 107(3): 288-303, 2023.
Article em En | MEDLINE | ID: mdl-34818261
ABSTRACT

BACKGROUND:

The aim of the study was to assess the effectiveness of the main classes of drugs used at reducing morbidity related to ureteric stents.

SUMMARY:

After establishing a priori protocol, a systematic electronic literature search was conducted in July 2019. The randomized clinical trials (RCTs) selection proceeded in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and was registered (PROSPERO ID 178130). The risk of bias and the quality assessment of the included RCTs were performed. Ureteral Stent Symptom Questionnaire (USSQ), International Prostate Symptom Score (IPSS), and quality of life (QoL) were pooled for meta-analysis. Mean difference and risk difference were calculated as appropriate for each outcome to determine the cumulative effect size. Fourteen RCTs were included in the analysis accounting for 2,842 patients. Alpha antagonist, antimuscarinic, and phosphodiesterase (PDE) inhibitors significatively reduced all indexes of the USSQ, the IPSS and QoL scores relative to placebo. Conversely, combination therapy (alpha antagonist plus antimuscarinic) showed in all indexes of the USSQ, IPSS, and QoL over alpha antagonist or antimuscarinic alone. On comparison with alpha blockers, PDE inhibitors were found to be equally effective for urinary symptoms, general health, and body pain parameters, but sexual health parameters improved significantly with PDE inhibitors. Finally, antimuscarinic resulted in higher decrease in all indexes of the USSQ, the IPSS, and QoL relative to alpha antagonist. KEY MESSAGE Relative to placebo, alpha antagonist alone, antimuscarinics alone, and PDE inhibitors alone have beneficial effect in reducing stent-related symptoms. Furthermore, there are significant advantages of combination therapy compared with monotherapy. Finally, PDE inhibitors are comparable to alpha antagonist, and antimuscarinic seems to be more effective than alpha antagonist alone.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ureter / Antagonistas Muscarínicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Qualitative_research / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ureter / Antagonistas Muscarínicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Qualitative_research / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article